Compare BLX & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLX | AUPH |
|---|---|---|
| Founded | 1977 | 1993 |
| Country | Panama | Canada |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | 1999 |
| Metric | BLX | AUPH |
|---|---|---|
| Price | $51.17 | $14.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 154.2K | ★ 836.9K |
| Earning Date | 02-12-2026 | 02-26-2026 |
| Dividend Yield | ★ 5.37% | N/A |
| EPS Growth | ★ 8.75 | N/A |
| EPS | ★ 6.09 | 0.55 |
| Revenue | ★ $317,451,000.00 | $265,808,000.00 |
| Revenue This Year | $18.17 | $21.76 |
| Revenue Next Year | $6.12 | $16.45 |
| P/E Ratio | ★ $8.40 | $25.87 |
| Revenue Growth | 10.87 | ★ 20.62 |
| 52 Week Low | $31.14 | $6.55 |
| 52 Week High | $51.49 | $16.54 |
| Indicator | BLX | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 72.48 | 38.73 |
| Support Level | $49.33 | $14.21 |
| Resistance Level | $49.78 | $14.66 |
| Average True Range (ATR) | 1.12 | 0.45 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 92.87 | 3.88 |
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.